Inspiremd reports third quarter 2023 financial results and provides business update

- presented positive 30-day follow-up results from the c-guardians u.s. investigational device exemption (ide) clinical trial demonstrating an overall major adverse events rate (dsmi) of 0.95% from procedure through 30 days at the vascular interventional advances annual meeting (viva23) –
NSPR Ratings Summary
NSPR Quant Ranking